First in Human Study With NG-641, a Tumour Selective Transgene Expressing Adenoviral Vector

Summary

To characterise the safety and tolerability of NG-641 in patients with metastatic or advanced epithelial tumours.

Timeline

Start

2020-01-23

Primary completion

2023-08-31

Completion

2023-12-20

Publications

• Khalil DN, Prieto Gonzalez-Albo I, Rosen L, Lillie T, Stacey A, Parfitt L, Soff GA. A tumor-selective adenoviral vector platform induces transient antiphospholipid antibodies, without increased risk of thrombosis, in phase 1 clinical studies. Invest New Drugs. 2023 Apr;41(2):317-323. doi: 10.1007/s10637-023-01345-8. Epub 2023 Mar 10.

Drugs

Indications